PCSK9: Associated with cardiac diseases and their risk factors?

Guo, Yanan; Yan, Bin-Jie; Tai, Shi; Zhou, Shenghua; Zheng, Xi-Long

doi:10.1016/j.abb.2020.108717

Cited by 27 publications

(26 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apoptotic, necrotic and autophagic cell death pathways play central roles in tissue injury caused by ischemia-reperfusion during myocardial infarction (MI) and are important therapeutic targets [14,45,46]. During ischemia caused by coronary artery occlusion, affected myocardial tissues downstream of the occlusion become progressively hypoxic and acidotic [11,35,47].…”

Section: Discussionmentioning

confidence: 99%

"Regulatory Roles for miR-126 in Inflammatory Response and Programmed Death of Cardiac Myocytes Driven by Acidosis During Simulated Ischemia"

Liu¹,

Zhang

Wei

et al. 2021

BJSTR

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

"Regulatory Roles for miR-126 in Inflammatory Response and Programmed Death of Cardiac Myocytes Driven by Acidosis During Simulated Ischemia"

Liu¹,

Zhang

Wei

et al. 2021

BJSTR

View full text Add to dashboard Cite

“…PCSK9 was found to be a biomarker that can predict cardiovascular events, even in those patients with controlled LDL-c plasma levels [61]. Accordingly, collective studies have demonstrated that PCSK9 directly promotes atherosclerosis by being involved in atherosclerotic inflammation [16][17][18]. Furthermore, recent studies suggested a novel role for PCSK9 in promoting atherosclerosis through platelet activation, a key role during atherogenesis and in atherothrombosis-induced MI [35,36,[62][63][64].…”

Section: Pcsk9 and MImentioning

confidence: 99%

“…This makes PCSK9 a potential target to be developed for the prevention and treatment of cardiovascular diseases. Accordingly, PCSK9 inhibitors were established and found to improve cardiac function in an acute myocardial infarction (AMI) rat model [18].…”

Section: Introductionmentioning

confidence: 99%

PCSK9 Promotes Cardiovascular Diseases: Recent Evidence about Its Association with Platelet Activation-Induced Myocardial Infarction

Puteri

Azmi

Kato

et al. 2022

Life

View full text Add to dashboard Cite

Cardiovascular diseases are the leading cause of death worldwide, with the majority of the cases being heart failure due to myocardial infarction. Research on cardiovascular diseases is currently underway, particularly on atherosclerosis prevention, to reduce the risk of myocardial infarction. Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been reported to play a role in lipid metabolism, by enhancing low-density lipoprotein (LDL) receptor degradation. Therefore, PCSK9 inhibitors have been developed and found to successfully decrease LDL plasma levels. Recent experimental studies have also implicated PCSK9 in platelet activation, having a key role during atherosclerosis progression. Although numerous studies have addressed the role of PCSK9 role in controlling hypercholesterolemia, studies and discussions exploring its involvement in platelet activation are still limited. Hence, here, we address our current understanding of the pathophysiological process involved in atherosclerosis-induced myocardial infarction (MI) through platelet activation and highlight the molecular mechanisms used by PCSK9 in regulating platelet activation. Undoubtedly, a deeper understanding of the relationship between platelet activation and the underlying molecular mechanisms of PCSK9 in the context of MI progression will provide a new strategy for developing drugs that selectively inhibit the most relevant pathways in cardiovascular disease progression.

show abstract

“…Increased expression of PCSK9 after acute myocardial infarction (AMI), triggered by hypoxia and ongoing inflammatory processes, leads to the activation of excessive apoptosis in cardiac cells resulting in heart muscle damage [ 87 ]. Negative effects of PCSK9 action, including heart remodeling or increase in infarct size, involve low-density lipoprotein receptor-related protein 1 (LRP1)—the target receptor for PCSK9 in ischemic heart [ 88 ].…”

Section: Pcsk9 and Heartmentioning

confidence: 99%

Insight into the Evolving Role of PCSK9

et al. 2022

View full text Add to dashboard Cite

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is the last discovered member of the family of proprotein convertases (PCs), mainly synthetized in hepatic cells. This serine protease plays a pivotal role in the reduction of the number of low-density lipoprotein receptors (LDLRs) on the surface of hepatocytes, which leads to an increase in the level of cholesterol in the blood. This mechanism and the fact that gain of function (GOF) mutations in PCSK9 are responsible for causing familial hypercholesterolemia whereas loss-of-function (LOF) mutations are associated with hypocholesterolemia, prompted the invention of drugs that block PCSK9 action. The high efficiency of PCSK9 inhibitors (e.g., alirocumab, evolocumab) in decreasing cardiovascular risk, pleiotropic effects of other lipid-lowering drugs (e.g., statins) and the multifunctional character of other proprotein convertases, were the cause for proceeding studies on functions of PCSK9 beyond cholesterol metabolism. In this article, we summarize the current knowledge on the roles that PCSK9 plays in different tissues and perspectives for its clinical use.

show abstract

PCSK9: Associated with cardiac diseases and their risk factors?

Cited by 27 publications

References 127 publications

"Regulatory Roles for miR-126 in Inflammatory Response and Programmed Death of Cardiac Myocytes Driven by Acidosis During Simulated Ischemia"

"Regulatory Roles for miR-126 in Inflammatory Response and Programmed Death of Cardiac Myocytes Driven by Acidosis During Simulated Ischemia"

PCSK9 Promotes Cardiovascular Diseases: Recent Evidence about Its Association with Platelet Activation-Induced Myocardial Infarction

Insight into the Evolving Role of PCSK9

Contact Info

Product

Resources

About